CN112384494A - 一种稠合三环γ-氨基酸衍生物的组合物及其制备 - Google Patents

一种稠合三环γ-氨基酸衍生物的组合物及其制备 Download PDF

Info

Publication number
CN112384494A
CN112384494A CN201980045729.1A CN201980045729A CN112384494A CN 112384494 A CN112384494 A CN 112384494A CN 201980045729 A CN201980045729 A CN 201980045729A CN 112384494 A CN112384494 A CN 112384494A
Authority
CN
China
Prior art keywords
microcrystalline cellulose
certain embodiments
weight percentage
formula
pain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980045729.1A
Other languages
English (en)
Other versions
CN112384494B (zh
Inventor
张轩邈
彭峰
毛华
邓娟娟
严庞科
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sichuan Haisco Pharmaceutical Co Ltd
Original Assignee
Sichuan Haisco Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sichuan Haisco Pharmaceutical Co Ltd filed Critical Sichuan Haisco Pharmaceutical Co Ltd
Publication of CN112384494A publication Critical patent/CN112384494A/zh
Application granted granted Critical
Publication of CN112384494B publication Critical patent/CN112384494B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

一种稠合三环γ‑氨基酸衍生物的药物组合物及其用途。所述药物组合物包含：(i)式(I)所式结构或其药学上可接受的盐为活性物质，重量百分比为1％～45％；(ii)任选的一种或多种填充剂，重量百分比为50％～95％；(iii)任选的一种或多种润滑剂，重量百分比为0.1％～5.5％；且所有组分的重量百分比总和为100％；其中式(I)结构药学上可接受的盐结构如式(I‑A)所示。
Figure DDA0002887065470000011

Description

PCT国内申请，说明书已公开。

Claims (27)

  1. PCT国内申请，权利要求书已公开。
CN201980045729.1A 2018-07-12 2019-07-12 一种稠合三环γ-氨基酸衍生物的组合物及其制备 Active CN112384494B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810756863 2018-07-12
CN201810756863X 2018-07-12
PCT/CN2019/095856 WO2020011257A1 (zh) 2018-07-12 2019-07-12 一种稠合三环γ-氨基酸衍生物的组合物及其制备

Publications (2)

Publication Number Publication Date
CN112384494A true CN112384494A (zh) 2021-02-19
CN112384494B CN112384494B (zh) 2024-08-06

Family

ID=69142171

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980045729.1A Active CN112384494B (zh) 2018-07-12 2019-07-12 一种稠合三环γ-氨基酸衍生物的组合物及其制备

Country Status (12)

Country Link
US (1) US20210186909A1 (zh)
EP (1) EP3822252A4 (zh)
JP (1) JP7222063B2 (zh)
KR (1) KR102515847B1 (zh)
CN (1) CN112384494B (zh)
AU (1) AU2019302611B2 (zh)
CA (1) CA3106382C (zh)
EA (1) EA202190126A1 (zh)
MX (1) MX2021000403A (zh)
TW (1) TWI808217B (zh)
WO (1) WO2020011257A1 (zh)
ZA (1) ZA202100181B (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4183771A4 (en) * 2020-07-20 2024-04-24 Sichuan Haisco Pharmaceutical Co., Ltd. SUSTAINED RELEASE PHARMACEUTICAL FORMULATION OF A CONDENSED TRICYCLIC T-AMINO ACID DERIVATIVE AND METHOD OF MANUFACTURING THE SAME

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004031124A1 (en) * 2002-10-04 2004-04-15 Pfizer Limited Cyclic nitromethyl acetic acid derivatives
WO2009041453A1 (ja) * 2007-09-28 2009-04-02 Daiichi Sankyo Company, Limited 二環性γ－アミノ酸誘導体
WO2010079668A1 (ja) * 2009-01-08 2010-07-15 第一三共株式会社 オレフィン化合物
WO2017114225A1 (zh) * 2015-12-31 2017-07-06 四川海思科制药有限公司 稠合三环γ-氨基酸衍生物及其制备方法和在医药上的应用
WO2018050046A1 (zh) * 2016-09-14 2018-03-22 四川海思科制药有限公司 稠合三环γ-氨基酸衍生物及其制备方法和在医药上的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1827095A (zh) * 2006-04-14 2006-09-06 北京润德康医药技术有限公司 一种以普瑞巴林为活性成分的药用组合物及其制备方法、用途
EP2076249A2 (en) * 2006-10-27 2009-07-08 FMC Corporation Dry granulation binders, products, and use thereof
KR102539234B1 (ko) * 2016-04-07 2023-06-02 에스케이케미칼 주식회사 은행잎 추출물을 포함하는 경구용 서방 제제

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004031124A1 (en) * 2002-10-04 2004-04-15 Pfizer Limited Cyclic nitromethyl acetic acid derivatives
WO2009041453A1 (ja) * 2007-09-28 2009-04-02 Daiichi Sankyo Company, Limited 二環性γ－アミノ酸誘導体
WO2010079668A1 (ja) * 2009-01-08 2010-07-15 第一三共株式会社 オレフィン化合物
WO2017114225A1 (zh) * 2015-12-31 2017-07-06 四川海思科制药有限公司 稠合三环γ-氨基酸衍生物及其制备方法和在医药上的应用
WO2018050046A1 (zh) * 2016-09-14 2018-03-22 四川海思科制药有限公司 稠合三环γ-氨基酸衍生物及其制备方法和在医药上的应用

Also Published As

Publication number Publication date
KR102515847B1 (ko) 2023-03-29
JP7222063B2 (ja) 2023-02-14
ZA202100181B (en) 2022-06-29
WO2020011257A1 (zh) 2020-01-16
KR20210028680A (ko) 2021-03-12
EP3822252A4 (en) 2021-11-17
TWI808217B (zh) 2023-07-11
TW202012362A (zh) 2020-04-01
AU2019302611A1 (en) 2021-02-25
MX2021000403A (es) 2021-03-25
CA3106382A1 (en) 2020-01-16
CA3106382C (en) 2023-11-07
CN112384494B (zh) 2024-08-06
EA202190126A1 (ru) 2021-06-30
EP3822252A1 (en) 2021-05-19
AU2019302611B2 (en) 2022-02-17
BR112021000398A2 (pt) 2021-04-06
JP2021525789A (ja) 2021-09-27
US20210186909A1 (en) 2021-06-24

Similar Documents

Publication Publication Date Title
TWI833686B (zh) Lsd1 抑制劑之調配物
TWI727949B (zh) 調節蛋白質激酶之化合物的固態形式
CN102351857A (zh) 盐酸托烷司琼化合物
CN113993590B (zh) 新型egfr抑制剂
CN102367252A (zh) 一种盐酸托烷司琼化合物
CN108218844B (zh) 一种美金刚帕罗西汀共晶盐及其制备方法、药物组合物、应用
TWI808217B (zh) 稠合三環γ-胺基酸衍生物之組合物及其製備方法
ES2650797T3 (es) Formas cristalinas de (S)-4-amino-N- (1-(4-clorofenil)-3-hidroxipropil)-1-(7H-pirrolo [2,3-d] pirimidin-4-il) piperidina-4-carboxamida
ES2651689T3 (es) Forma salina de alfa-6-mPEG6-O-hidroxicodona sólida como antagonista opioide y usos de la misma
JP6522094B2 (ja) ４−［２−ジメチルアミノ−１−（１−ヒドロキシシクロヘキシル）エチル］フェニル４−メチルベンゾエートヒドロクロリドの多形体、それらを作製する方法及びそれらの使用
WO2020011258A1 (zh) 稠合三环γ-氨基酸衍生物的盐的晶型及制备和应用
EA045716B1 (ru) Композиция конденсированных трициклических производных гамма-аминокислоты для лечения и/или предупреждения механической боли и её приготовление
CN109721557A (zh) 来曲唑晶ii型固体物质及制备方法和其药物组合物与用途
US11680046B2 (en) Crystalline (R)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylate, compositions and methods of use thereof
TW200837067A (en) Ascomycin and pimecrolimus having reduced levels of desmethylascomycin and 32-deoxy-32-epichloro-desmethylascomycin respectively, and methods for preparation thereof
BR112021000398B1 (pt) Composição de derivados de aminoácidos gama tricíclicos fundidos e a preparação dos mesmos
WO2022082100A1 (en) Cocrystals of l-4-chlorokynurenine, compositions and therapeutic uses thereof
WO2018227430A1 (zh) 一种晶vii型物质及其制备方法、药物组合物与用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40038397

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant